Abstract Pazopanib is approved for metastatic renal cell carcinoma (mRCC) and soft tissue sarcoma (STS) in a dose of 800 mg once daily (QD) taken under fasted conditions. In clinical practice, approximately 60% of patients require dose reductions due to toxicity, with severe liver toxicity necessitating treatment interruptions in over 10% of cases. While a trough concentration (Cmin,ss) target of ≥ 20.5 mg/L has been established for mRCC efficacy, no specific threshold exists for liver toxicity.
van der Hulle
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with van
Contact van, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack